In clinical trials
Brain & sleep
NNZ-2591
Evidence
Clinical trials
Class
Synthetic analog of cyclic glycine-proline
KEY TAKEAWAY
NNZ-2591 is a synthetic version of cyclic glycine-proline, a small molecule related to a breakdown product of IGF-1. It is being developed as an oral drug for rare neurodevelopmental disorders. NNZ-2591 is not FDA-approved and is still being tested in clinical trials.
Written by the Veylo editorial team · Updated
November 2026
What it is
Synthetic analog of cyclic glycine-proline
Being studied for
Studied in rare neurodevelopmental conditions such as Phelan-McDermid and Angelman syndromes
Key fact
NNZ-2591 is not FDA-approved and is still being tested in clinical trials.
Route
Oral liquid in trials
Evidence strength
Clinical trials
NNZ-2591 is a synthetic version of cyclic glycine-proline, a small molecule related to a breakdown product of IGF-1. It is being developed as an oral drug for rare neurodevelopmental disorders.
It is thought to help regulate IGF-1 signaling and reduce inflammation in the brain, which may support healthy development of nerve connections.
NNZ-2591 is not FDA-approved and is still being tested in clinical trials.
Studied in rare neurodevelopmental conditions such as Phelan-McDermid and Angelman syndromes.
Early studies described it as generally well tolerated, but safety data are still limited.
NNZ-2591: see PubMed and ClinicalTrials.gov for published studies and registered trials. No FDA drug label exists for the uses described.
Veylo content is educational and not medical advice. Peptides that are not FDA-approved are not approved for the uses described.